ArticlebioRxiv : the preprint server for biology2025
The endo-lysosomal system drives lumen formation in a human epiblast model.
Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
8 authors.
Funding
Abstract
The formation of a central lumen in the epiblast is a critical step that occurs during implantation in the human embryo. Lumen formation is accompanied by highly dynamic and complex cargo trafficking in the endo-lysosomal system. However, our understanding of key players and machineries that control this critical trafficking process remains incomplete in the context of epiblast development. Here, we explored endo-lysosomal dynamics that are associated with the generation of the apicosome, the earliest stage of lumen formation in a model of human epiblast development based on human pluripotent stem cells. We uncovered a hybrid early/late endosome compartment as well as a previously unrecognized dynamics of late endosome and lysosome compartments in trafficking podocalyxin (PODXL), a sialomucin glycoprotein that helps to establish and maintain the open lumen, during apicosome formation. To gain molecular insight into these unique hybrid endosome and late endosome/lysosome machineries in PODXL traffic, we used APEX2-based spatial proteomics to identify PODXL-proximity partners during apicosome formation, and identified RAB35, a Rab small GTPase known to control PODXL traffic as well as early and late endosome dynamics, as a key player in controlling apicosome formation. Our results suggest that RAB35 limits excess apicosome formation by promoting the early to late endosome transition as well as lysosome formation, which help to reduce PODXL to a level necessary for single apicosome formation. Overall, this study reveals novel endo-lysosomal mechanisms that contribute to apical membrane morphogenesis in a human model of epiblast formation.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.